Bisphenol A: FDA Analysis Mistakes and Redesign Opportunities

Wonder how FDA concluded BPA levels in people were too low to matter? False assumptions and circular logic…

  • Where the FDA went wrong
  • Risks of using existing substitutes
  • Designing endocrine disruption out of new chemicals
More information

Have your say ! Share your views